Magnesium sulfate
No admixture requiredFull monograph review pending
Historical dilution reference. Verify the preparation against the label for the product in hand.
Original GlobalRPh article: Magnesium Sulfate (opens in a new tab)Original source URL: https://globalrph.com/dilution/magnesium-sulfate/ Retrieved 2026-11-04
Historical source details
Original publication date: unavailable in the retrieved article.
Source location and file checksums
- Original source URL
- https://globalrph.com/dilution/magnesium-sulfate/ (opens in a new tab)
- Source date
- Not established in the retrieved source
- Retrieved
- 2026-11-04T19:48:14.292453+00:00
- Source location
- div.post-content
- Packaged content SHA-256
- 7db8b9b3d8a68f07917cecff6c70b7c6c3260877507cd05ce4ec99f71c102d33
- Original response SHA-256
- c81fdc08bfa40e3fd4d88169b77274d32e8dad40ab168a5083745b35b7031bd6
- Source body SHA-256
- 78e3b1f7605161720cc46c7937a308bfd49985dc9d62ea7eed1ad76becb92bb8
MAGNESIUM SULFATE |
|||||||||||||||||||||||||||||||||
| The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. | |||||||||||||||||||||||||||||||||
Usual Diluents |
|||||||||||||||||||||||||||||||||
| D5W, NS | |||||||||||||||||||||||||||||||||
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] |
|||||||||||||||||||||||||||||||||
| [1 gram] [ 50 ml] [30 min] [2 grams] [100 ml] [60 min] [3 grams] [100 ml] [2 hours] [4 grams] [250 ml] [3 hours] --------------------------- |
|||||||||||||||||||||||||||||||||
Stability / Miscellaneous |
|||||||||||||||||||||||||||||||||
| 1 gram = 8.12 meq. Maximum rate: 1 gram/ 7 minutes.Normal range:1.5 to 2.5 meq/L or 1.7 to 2.6 mg/dl.Magnesium content: Mag Oxide: 49.6 meq/gram Mag Gluconate: 4.5 meq/gram MOM: @ 13.4 meq/5 ml -------------------------------------------------------------------------------- DOSAGE AND ADMINISTRATION (Package insert) Both intravenous and intramuscular administration are appropriate. Intramuscular administration of the undiluted 50% solution results in therapeutic plasma levels in 60 minutes, whereas I.V. doses will provide a therapeutic level almost immediately. The rate of I.V. injection should generally not exceed 150 mg/minute (1.5 mL of a 10% concentration or its equivalent), except in severe eclampsia with seizures (see below). Solutions for intravenous infusion must be diluted to a concentration of 20% or less prior to administration. The diluents commonly used are 5% Dextrose Injection, USP and 0.9% Sodium Chloride Injection, USP. Deep intramuscular injection of the undiluted (50%) solution is appropriate for adults, but the solution should be diluted to a 20% or less concentration prior to such injection in children. In Magnesium Deficiency In Hyperalimentation In Eclampsia Other Uses For controlling seizures associated with epilepsy, glomerulonephritis or hypothyroidism, the usual adult dose is 1 g administered I.M. or I.V. In paroxysmal atrial tachycardia, magnesium should be used only if simpler measures have failed and there is no evidence of myocardial damage. The usual dose is 3 to 4 g (30 to 40 mL of a 10% solution) administered I.V. over 30 seconds with extreme caution. For reduction of cerebral edema, 2.5 g (25 mL of a 10% solution) is given I.V. Incompatibilities
The potential incompatibility will often be influenced by the changes in the concentration of reactants and the pH of the solutions. It has been reported that magnesium may reduce the antibiotic activity of streptomycin, tetracycline and tobramycin when given together. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. HOW SUPPLIED
Do not administer unless solution is clear and container is undamaged. Discard unused portion. ©Hospira 2004 Source: [package insert] |
U.S. label preparation
Baxter magnesium sulfate in water for injection, single-dose flexible containers · No admixture required
- Preparation
- Select the labeled infusion bag. The listed presentations contain 2 g/50 mL, 3 g/100 mL, 4 g/100 mL or 4 g/50 mL. The 4 g bags have different concentrations.
- Administration and handling
- These bags are for IV infusion only. Inspect the solution for clarity and discard the unused portion. Refer to the label for indication-specific administration and monitoring.
Product and source details
Baxter Healthcare Corporation · ANDA211966
Product NDC: 0338-1708, 0338-1715, 0338-1719, 0338-6353
SPL effective 2026-01-09 | SPL version 12. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Selected product identity
The selected product is identified for this preparation.
View product identifiers and primary-label provenance
- Selected product scope
- Baxter magnesium sulfate in water for injection, single-dose flexible containers
- Labeler
- Baxter Healthcare Corporation
- Application number(s)
- ANDA211966
- NDC(s)
- 0338-1708; 0338-1715; 0338-1719; 0338-6353
- DailyMed Set ID
- ea05b8f9-6e11-45c3-824a-4a78818019df
- SPL version
- 12
- Label printed revision date
- Not established
- SPL effective date
- 2026-01-09
- Retrieved
- 2026-11-13
- Downloaded XML SHA-256
- 59c5fcad20bed8b56dfcd063da20cb67209693c58c8ae9c13cd7fb8a57a0d9f5
Selected label Baxter magnesium sulfate in water for injection, single-dose flexible containers
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.
Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)